Research and treatment progress on post-transplantation diabetes mellitus caused by tacrolimus

doi:10.3877/cma.j.issn.1674-3903.2017.01.011

Abstract

Abstract:

Post-transplantation diabetes mellitus (PTDM) is one of the most common and severe complications after solid organ transplantation. PTDM is a high risk factor for graft dysfunction, infection, cardiovascular complications and acute graft rejection, which affected survival rate and the quality of life of recipients. Tacrolimus is a powerful kind of immunosuppressant which is widely used on organ recipients. However, tacrolimus is more diabetogenic than other kind of immunosuppressant. Here we summarized the research and treatment progress of tacrolimus on PTDM.

Key words: Tacrolimus, Immunosuppressant, Post-transplantation diabetes mellitus

Lu Li, Huizhen Chen, Xingguang Liang, Yahong Wu, Shenghua Yang, Yujie Huang, Mingzhu Huang. Research and treatment progress on post-transplantation diabetes mellitus caused by tacrolimus[J]. Chinese Journal of Transplantation(Electronic Edition), 2017, 11(01): 44-49.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2017.01.011

https://zhyzzz.cma-cmc.com.cn/EN/Y2017/V11/I01/44

References 54

1	Hameed AM,Hawthorne WJ,Pleass HC. Advances in organ preservation for transplantation[J]. ANZ J Surg, 2016.
2	Shivaswamy V,Boerner B,Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61.
3	Han E,Kim MS,Kim YS, et al. Risk assessment and management of post-transplant diabetes mellitus[J]. Metabolism, 2016, 65(10): 1559-1569.
4	Sharif A. Treatment options for post-transplantation diabetes mellitus[J]. Curr Diabetes Rev, 2015, 11(3): 155-162.
5	Haidinger M,Antlanger M,Kopecky C, et al. Post-transplantation diabetes mellitus: evaluation of treatment strategies[J]. Clin Transplant, 2015, 29(5): 415-424.
6	Liu J,Farmer JJ,Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes[J]. Cell, 1991, 66(4): 807-815.
7	Abou-Jaoude MM,Najm R,Shaheen J, et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients[J]. Transplant Proc, 2005, 37(7): 3025-3028.
8	Morris-Stiff G,Ostrowski K,Balaji V, et al. Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases[J]. Transpl Int, 1998, 11(Suppl 1): S334-S336.
9	Vincenti F,Friman S,Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus[J]. Am J Transplant, 2007, 7(6): 1506-1514.
10	Kasiske BL,Snyder JJ,Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States[J]. Am J Transplant, 2003, 3(2): 178-185.
11	Ghisdal L,Van Laecke S,Abramowicz MJ, et al. New-onset diabetes after renal transplantation: risk assessment and management[J]. Diabetes Care, 2012, 35(1): 181-188.
12	Collins AJ,Foley RN,Chavers B, et al. United States Renal Data System 2011 annual data report: Atlas of chronic kidney disease & end-stage renal disease in the United States[J]. Am J Kidney Dis, 2012, 59(1 Suppl 1): A7, e1-e420.
13	Lee S,Moon JY,Lee SH, et al.Angiotensinogen polymorphisms and post-transplantation diabetes mellitus in Korean renal transplant subjects[J]. Kidney Blood Press Res, 2013, 37(2-3): 95-102.
14	Weng LC,Chiang YJ,Lin MH, et al. Association between use of FK506 and prevalence of post-transplantation diabetes mellitus in kidney transplant patients[J]. Transplant Proc, 2014, 46(2): 529-531.
15	Filler G,Webb NJ,Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs cyclosporin microemulsion[J]. Pediatr Transplant, 2005, 9(4): 498-503.
16	Yao B,Chen X,Shen FX, et al. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism[J]. Transplant Proc, 2013, 45(1): 194-196.
17	Heisel O,Heisel R,Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis[J]. Am J Transplant, 2004, 4(4): 583-595.
18	Prokai A,Fekete A,Pasti K, et al. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus[J]. Pediatr Diabetes, 2012, 13(1): 81-91.
19	Burroughs TE,Swindle JP,Salvalaggio PR, et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients[J]. Transplantation, 2009, 88(3): 367-373.
20	Al-Uzri A,Stablein DM,A Cohn R. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)[J]. Transplantation, 2001, 72(6): 1020-1024.
21	Hathout E,Alonso E,Anand R, et al. Post-transplant diabetes mellitus in pediatric liver transplantation[J]. Pediatr Transplant, 2009, 13(5): 599-605.
22	Hathout EH,Chinnock RE,Johnston JK, et al. Pediatric post-transplant diabetes: data from a large cohort of pediatric heart-transplant recipients[J]. Am J Transplant, 2003, 3(8): 994-998.
23	Prokai A,Fekete A,Kis E, et al. Post-transplant diabetes mellitus in children following renal transplantation[J]. Pediatr Transplant, 2008, 12(6): 643-649.
24	Kuo HT,Poommipanit N,Sampaio M, et al. Risk factors for development of new-onset diabetes mellitus in pediatric renal transplant recipients: an analysis of the OPTN/UNOS database[J]. Transplantation, 2010, 89(4): 434-439.
25	Garro R,Warshaw B,Felner E. New-onset diabetes after kidney transplant in children[J]. Pediatr Nephrol, 2015, 30(3): 405-416.
26	Redmon JB,Olson LK,Armstrong MB, et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells[J]. J Clin Invest, 1996, 98(12): 2786-2793.
27	van Hooff JP,Christiaans MH,van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus[J]. Nephrol Dial Transplant, 2004, 19(6 Suppl): S8-S12.
28	Boots JM,van Duijnhoven EM,Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction[J]. J Am Soc Nephrol, 2002, 13(1): 221-227.
29	Rodrigo E,Pinera C,de Cos MA, et al. Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation[J]. Transpl Int, 2005, 18(10): 1152-1157.
30	Webster A,Woodroffe RC,Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients[J]. Cochrane Database Syst Rev, 2005, 4: CD003961.
31	Tamura K,Fujimura T,Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell[J]. Transplantation, 1995, 59(11): 1606-1613.
32	Drachenberg CB,Klassen DK,Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation[J]. Transplantation, 1999, 68(3): 396-402.
33	Shivaswamy V,Bennett RG,Clure CC, et al. Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats[J]. Transl Res, 2014, 163(3): 221-231.
34	Johnson JD,Ao Z,Ao P, et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets[J]. Cell Transplant, 2009, 18(8): 833-845.
35	Heit JJ,Apelqvist AA,Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function[J]. Nature, 2006, 443(7109): 345-349.
36	Soleimanpour SA,Crutchlow MF,Ferrari AM, et al. Calcineurin signaling regulates human islet {beta}-cell survival[J]. J Biol Chem, 2010, 285(51): 40050-40059.
37	Speckmann T,Sabatini PV,Nian C, et al. Npas4 Transcription factor expression is regulated by calcium signaling pathways and prevents tacrolimus-induced cytotoxicity in pancreatic beta cells[J]. J Biol Chem, 2016, 291(6): 2682-2695.
38	Rostambeigi N,Lanza IR,Dzeja PP, et al. Unique cellular and mitochondrial defects mediate FK506-induced islet beta-cell dysfunction[J]. Transplantation, 2011, 91(6): 615-623.
39	Romanowski M,Dziedziejko V,Maciejewska-Karlowska A, et al. Adiponectin and leptin gene polymorphisms in patients with post-transplant diabetes mellitus[J]. Pharmacogenomics, 2015, 16(11): 1243-1251.
40	Filippatos TD,Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function[J]. World J Diabetes, 2013, 4(5): 190-201.
41	Sanyal D,Gupta S,Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting[J]. Indian J Endocrinol Metab, 2013, 17(Suppl 1): S203-S205.
42	Soliman AR,Fathy A,Khashab S, et al. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant[J]. Exp Clin Transplant, 2013, 11(6): 494-498.
43	Lane JT,Odegaard DE,Haire CE, et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation[J]. Transplantation, 2011, 92(10): e56-e57.
44	Haidinger M,Werzowa J,Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation-a randomized, double-blind, placebo-controlled trial[J]. Am J Transplant, 2014, 14(1): 115-123.
45	Werzowa J,Hecking M,Haidinger M, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial[J]. Transplantation, 2013, 95(3): 456-462.
46	Hecking M,Werzowa J,Haidinger M, et al. Novel views on new-onset diabetes after transplantation：development, prevention and treatment[J]. Nephrol Dial Transplant, 2013, 28(3): 550-566.
47	Davidson J,Wilkinson A,Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines[J]. Transplantation, 2003, 75(10 Suppl): S3-S24.
48	Kurian B,Joshi R,Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients[J]. Endocr Pract, 2008, 14(8): 979-984.
49	Wissing KM,Pipeleers L. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment[J]. Transplant Rev (Orlando), 2014, 28(2): 37-46.
50	Luther P,Baldwin DJ. Pioglitazone in the management of diabetes mellitus after transplantation[J]. Am J Transplant, 2004, 4(12): 2135-2138.
51	Pietruck F,Kribben A,Van TN, et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation[J]. Transpl Int, 2005, 18(4): 483-486.
52	Villanueva G,Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus[J]. Transplantation, 2005, 80(10): 1402-1405.
53	Juan KM,Ping CC. Prevention and management of new-onset diabetes mellitus in kidney transplantation[J]. Neth J Med, 2014, 72(3): 127-134.
54	Hecking M,Haidinger M,Doller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation[J]. J Am Soc Nephrol, 2012, 23(4): 739-749.

[1]	Hao Deng, Kui Su, Lihua Jia, Qianshu Lyu, Yingzi Ouyang. Clinical study of Er: YAG laser combined with tacrolimus ointment in the treatment of oral lichen planus [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2022, 16(04): 219-223.
[2]	Chunrong Ju, Jianxing He, Nanshan Zhong. The application and future prospects of mizoribine in the field of organ transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 227-231.
[3]	Jun Li, Tieyan Fan, Xinxin Niu, Hong Chen. Iron deficiency anemia caused by tacrolimus after liver transplantation: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 169-170.
[4]	Luhao Liu, Yongxin Su, Lijuan Zeng, Peng Zhang, Rongxin Chen, Lu Xu, Guanghui Li, Jiali Fang, Junjie Ma, Zheng Chen. Drug compliance of immunosuppressant in kidney transplant recipients during the COVID-19 pandemic [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 140-145.
[5]	Ye Xu, Jing Li, Ranjia Liu, Chen Pan, Mingxing Guo, Xiangli Cui. Analysis of the use of immunosuppressants after liver transplantation in 95 hospitals in China during 2017-2021 [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 134-139.
[6]	Min Tian, Bo Wang, Xuemin Liu, Xiaogang Zhang, Kun Guo, Yu Li, Liangshuo Hu, Jinxia Huo, Yi Lyu. Relevant research between high intrapatient variability in tacrolimus and immune-mediated graft injury after liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(02): 65-71.
[7]	Wenqing Xie, Suya Wang, Wenhan Peng, Junhao Lyu, Zhechi He, Jianghua Chen. Clinical study on allograft acute rejection at metaphase and long-term after kidney transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(01): 32-37.
[8]	Caitao Dong, Dawei Zhou, Juntao Liang, Qifa Ye. The progress of immunosuppressive therapy for IgA nephropathy patients underwent kidney transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(06): 365-369.
[9]	Zhengli Wan, Yi Li, Yamei Li, Yunfei An, Lin Yan, YangJuan Bai, Lanlan Wang, Yunying Shi. Intra-individual variation of tacrolimus and its related factors on renal insufficiency after transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(02): 71-76.
[10]	Lu Li, Xi Yang, Lijuan Zhao, Mingzhu Huang. Analysis and identification of differential expressed genes and functional pathways in islets of tacrolimus induced post-transplantation hyperglycemia [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(01): 1-10.
[11]	Wenbin Song, Kuifen Ma, Xingde Li, Yang Zhang, Cangsang Song. The mechanisms of gastrointestinal symptoms induced by immunosuppressive agents in kidney transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2020, 14(01): 58-61.
[12]	Yina Zhou, Dewei Zhao, Xudong Chen, Shaoling Zheng. The influence of tacrolimus on the expression of peroxisome proliferator-activated receptor-γ in renal transplantation recipients with new onset diabetes after transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2019, 13(04): 293-297.
[13]	Zhenyuan Xu, Qiang Xue, Yuanyu Zhao. Clinical therapeutics of post-transplantation diabetes mellitus [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(03): 231-234.
[14]	Longye Zhang, Weiping Liu, Yanfen Zhang, Yongli Guo, Renping Guan, Xue Shao, Zhaoyu Wang, Can Li. Protective effect of pancreatic kininogenase on tacrolimus-induced kidney injury in rats [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(04): 198-204.
[15]	Jianjun Ma, Yao Chen, Yamei Li, Yangjuan Bai, Yuangao Zou, Jiangtao Tang. Relationship between high intra-patient variability of tacrolimus and transplant outcome in renal transplant recipients [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2019, 07(03): 156-161.

Please choose a citation manager

Content to export